Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Video Insights
Advertisement
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Dr. Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ BTC.
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Dina Ioffe, MD, Fox Chase Cancer Center, talks about the use of immunotherapy in the neoadjuvant or adjuvant setting.
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
Low-dose aspirin halved recurrence in resected PIK3CA-mutated colorectal cancer, per data from the ALASCCA trial.
Dr. Michael Foote breaks down the CheckMate 8HW trial and supports dual immunotherapy as a first-line option in dMMR CRC.
Dr. Foote discusses the BREAKWATER trial and the impact of BRAF-targeted therapy in metastatic colorectal cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.